The reiteration of a Buy rating and maintenance of a $35 price target by a reputable analyst like Serge Belanger from Needham is likely to instill confidence among investors and could positively influence KalVista Pharma's stock price in the short term. Analyst ratings, especially with a high price target relative to current trading levels, can lead to increased investor interest and potentially drive up the stock price.